A Trial of SHR-1819 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2020

Primary Completion Date

March 7, 2022

Study Completion Date

March 7, 2022

Conditions

Healthy Volunteers

Interventions

DRUG

SHR-1819

SHR-1819 will be subcutaneously administered with different dose levels

DRUG

Placebo

Placebo will be subcutaneously administered with different dose levels

Trial Locations (1)

Atridia Pty Limited, Sydney

All Listed Sponsors

lead

Atridia Pty Ltd.

INDUSTRY

NCT04561128 - A Trial of SHR-1819 in Healthy Subjects | Biotech Hunter | Biotech Hunter